Guinea pig-anti-ASPA polyclonal antibody
Catalog No: OB-PGP013
Host Species: Guinea pig polyclonal antibodies
Important Notice: Antigen retrieval is required before IHC/IF staining.
Gene Synonyms: ASPA, aspartoacylase, Nur7, ACY2, ASP
Species Reactivity: Mouse, Rat; Predict to work in primates; Others have not been tested
Applications: IF/IHC: 1:100~500 WB: 1:1000
Antigen Retrieval: For an alternative approach, tissue sections could be incubated in 1x Citrate antigen retrieval solution for 30 min at 85°C and cool down to room temperature before next procedure.
Immunogen: Mouse ASPA peptide fused to GST.
Purification: Affinity purification
General Notes: FOR RESEARCH USE ONLY
Storage Buffer: pH7.4, PBS, 55mM Tris, 50mM Glycine, ~40% Glycerol, 0.1% potassium sorbate
Storage: Shipped at 4°C. Store at -20°C/4°C for months and -80°C for years. Avoid freeze/thaw cycle.
Background: ASPA catalyzes deacetylation of N-acetylaspartate (NAA), a highly abundant amino acid derivative in the central nervous system (CNS), to generate free acetate in the brain [1]. Mutations in ASPA protein cause Canavan disease (CD), an autosomal recessive neurodegenrative disorder that results in death [2,3].
In rodent CNS, ASPA is expressed in mature oligodendrocytes (OLs) [4,5]. Importantly, expression of ASPA in oligodendrocytes is much later than that of other differentiating OL markers, including MBP, PLP and MYRF. ASPA deficiency in mice affects early postnatal development of oligodendrocytes and myelination, results in severe vacuolation in the spinal cord and cause spongy degeneration of the CNS [3,6,7]. Notably, as immunohistochemistry showed cytoplasmic and nuclear staining [8], ASPA is suitable for number calculation of mature OLs in the CNS.
[1] D'Adamo AF, Jr., et al. Exp Brain Res. 1968; DIO: 10.1007/bf00235902
[2] Matalon R, et al. J Pediatr. 1995; DIO: 10.1016/s0022-3476(95)70105-2
[3] Traka M, et al. J Neurosci. 2008; DIO: 10.1523/jneurosci.1490-08.2008
[4] Klugmann M, et al. 2003; DIO: 10.1097/00001756-200310060-00016
[5] Kirmani BF, et al. 2003; DIO: 10.1016/S0165-3806(02)00592-8
[6] Mattan NS, et al. Neurobiol Dis. 2010; DIO: 10.1016/j.nbd.2010.07.003
[7] Surendran S, et al. Neurobiol Dis. 2005; DIO: 10.1016/j.nbd.2004.10.014
[8] Hershfield JR, et al. FASEB J. 2006; DIO: 10.1096/fj.05-5358fje
Key Words: Canavan disease, oligodendrocyte, mature oligodendrocyte, terminal differentiated oligodendrocyte, myelinating, myelin, acetyl CoA, N-acetylaspartate